Skip to main content
SpringerLink
Log in

The Intriguing Relationship of Helicobacter Pylori Infection and Gastro-Oesophageal Reflux Disease

  • Chapter
Gastroesophageal Reflux Disease

  • 1872 Accesses

Conclusion

The interesting pathophysiological interaction between Helicobacter pylori infection, type of gastritis, acid secretion and GORD complicated by weakness of study designs with small numbers of patients should not lead to confusion. The risk of gastric carcinogenesis and peptic ulcer formation against the need for possible higher doses of acid suppressive therapy for symptom control after eradication should be balanced carefully and can only lead us to one conclusion: there are more reasons that favour Helicobacter pylori eradication than to leave the bug in the stomach of your patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Kang JY (2004) Geographical and ethnic differences in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 20: 705–717

    Article  PubMed  CAS  Google Scholar 

  2. Delaney BC (2004) Prevalence and epidemiology of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 20(Suppl 8): 2–4

    Article  PubMed  Google Scholar 

  3. Koike T, Ohara S, Sekine H (2001) Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 1: 330–334

    Article  Google Scholar 

  4. Loffeld FJLF, Werdmuller BFM, Kuster JA (2000) Colonization with cagA positive Helicobacter pylori prevastrains inversely associated with reflux esophagitis and Barrett’s esophagus. Digestion 62: 95–99

    Article  PubMed  CAS  Google Scholar 

  5. Vicari JJ, Peek RM, Falk GW (1998) The seroprevalence of cagA positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 115: 50–57

    Article  PubMed  CAS  Google Scholar 

  6. Fallone CA, Barkun AW, Friedman G (2000) Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 95: 914–920

    Article  PubMed  CAS  Google Scholar 

  7. Raghunath A, Pali A, Hungin S (2003) Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 326: 737–739

    Article  PubMed  Google Scholar 

  8. Wu JCY, Sung Jy, Ng EK (1999) Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: a study from the East. Am J Gastroenterol 94: 1790–1794

    Article  PubMed  CAS  Google Scholar 

  9. O’Connor HJ (1999) Helicobacter pylori and gastro-oeosphagela reflux disease — clinical implications and management. Aliment Pharmacol Ther 13: 117–127

    Article  PubMed  CAS  Google Scholar 

  10. Labenz J, Malfertheiner P (1997) Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut 41: 277–280

    Article  PubMed  CAS  Google Scholar 

  11. Koike T, Ohara S, Sekine H (1999) Helicobacter pylori infection inhibits reflux oesophagitis by inducing atrophic gastritis. Am J Gastroenterology 94: 3468–3472

    Article  CAS  Google Scholar 

  12. Yamaji Y, Mitsushima T, Ikuma H (2001) Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oeosphagitis compared with gastric cancer: analysis of 5732 Japanese subjects. Gut 49: 335–340

    Article  PubMed  CAS  Google Scholar 

  13. El Serag Hb, Sonnenberg Am, Jamal MM (1999) Corpus gastritis is protective against reflux oesophagitis. Gut 45: 181–185

    Article  PubMed  Google Scholar 

  14. Hamada H, Haruma K, Mihara M (2000) High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 14: 729–735

    Article  PubMed  CAS  Google Scholar 

  15. Koike T, Ohara S, Sekine H (2001) Increased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing reflux oeosphagitis. Aliment Pharmacol Ther 15: 813–820

    Article  PubMed  CAS  Google Scholar 

  16. El-Omar EM, Oien K, El-Nujumi A (1997) Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 113: 15–24

    Article  PubMed  CAS  Google Scholar 

  17. Feldman M, Cryer B, Sammer D (1999) Influence of Helicobacter pylori infection on meal stimulated gastric acid secretion and gastroesophageal reflux. Am J Physiol 277: G1159–G1164

    PubMed  CAS  Google Scholar 

  18. Wu JC, Chan FK, Wang SK (2002) Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux esophagitis. Aliment Pharmacol Ther 16: 545–552

    Article  PubMed  CAS  Google Scholar 

  19. Verdu EF, Armstrong D, Fraser R (1995) Effect of Helicobacter pylori status on intergastric pH during treatment with omeprazole. Gut 37: 743–748

    PubMed  CAS  Google Scholar 

  20. Bercik P, Verdu EF, Armstrong D (2000) The effect of ammonia on omeprazole induced reduction of gastric acidity in subjects with Helicobacter pylori infection. Am J Gastroenterol 95: 947–955

    Article  PubMed  CAS  Google Scholar 

  21. Gillen D, Wirz AA, Ardill JE (1999) Rebound hyper-secretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 116: 239–247

    Article  PubMed  CAS  Google Scholar 

  22. Adamek RJ, Behrendt J, Wenzel C (2001) Relapse and prevention in reflux oeosphagitis with regard to Helicobacter pylori status: a double-blinded randomised, multicenter trial to compare the efficacy of pantoprazole versus ranitidine. Eur J Gastroenterol Hepatol 13: 811–817

    Article  PubMed  CAS  Google Scholar 

  23. Labenz J, Blum AL, Bayerdorffer E (1997) Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112: 1442–1447

    Article  PubMed  CAS  Google Scholar 

  24. Telfera S, Hatlebakk JG, Berstad A (1999) The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Ther 13: 915–920

    Article  Google Scholar 

  25. Moayyedi P, Bardhan C, Young L (2001) Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 121: 1120–1126

    Article  PubMed  CAS  Google Scholar 

  26. Manifold DK, Anggiansah A, Rowe I (2001) Gastrooesophageal reflux and duodenogastric reflux before and after eradication in Helicobacter pylori gastritis. Eur J Gastroenterol Hepatol 13: 535–539

    Article  PubMed  CAS  Google Scholar 

  27. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkman JJ, Festen HPM, Dent J, Zeitoun P, Havu N, Lamm M, Walan A (2004) Cure of Helicobacter pylori infection in pateintes with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 53: 12–20

    Article  PubMed  CAS  Google Scholar 

  28. Schwizer W, Thurmshirn M, Dent J (2001) Helicobacter pylori and symptomatic relapse of gastro-esophageal reflux disease: a randomized controlled trial. Lancet 357: 1738–1742

    Article  PubMed  CAS  Google Scholar 

  29. El Omar E, Perman I, Dorrian CA (1993) Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in duodenal ulcer patients. Gut 34: 1060–1065

    PubMed  Google Scholar 

  30. Kupcinskas L, Jonaitis L, Kudelis G (2004) A 1 year follow-up study of the consequences of Helicobacter pylori eradication in duodenal ulcer patients: unchanged frequency of erosive oesophagitis and decreased preva lence of non-erosive gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 16: 369–374

    Article  PubMed  Google Scholar 

  31. Rokkas T, Ladas S, Triantafyllou K (2001) The association between CagA status and the development of esophagitis after the eradication of Helicobacter pylori. Am J Med 110: 703–707

    Article  PubMed  CAS  Google Scholar 

  32. Warburton-Timms VJ, Charlett A, Valori RM (2001) The significance of cagA+ Helicobacter pylori in reflux oesophagitis. Gut 49: 341–346

    Article  PubMed  CAS  Google Scholar 

  33. Jakobs R, Riemann JF (2004) CagA-positive Helicobacter pylori strains and gastrooesophageal erflux disease: still puzzling. European Jounal of Gastroenterol Hepatol 16: 635–637

    Article  CAS  Google Scholar 

  34. Wu JCY, Chan FKL, Ching JYL, Leung W-K, Hui Y, Leong R, Chung SCS, Sung JJY (2004) Effect of Helicobacter pylori eradication on treatment of gastrooesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut 53: 174–179

    Article  PubMed  CAS  Google Scholar 

  35. Labenz J, Tillenburg B, Peitz U (1996) Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 110: 725–732

    Article  PubMed  CAS  Google Scholar 

  36. Martinek J, Kuzela I, Spicak J (2000) Review article: the clinical influence of Helicobacter pylori in effective acid suppression — implications for the treatment of gastroesophageal reflux disease. Aliment Pharmacol Ther 14: 979–990

    Article  PubMed  CAS  Google Scholar 

  37. Holtmann G, Cain C, Malfertheiner P (1999) Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazoel. Gastroenterology 117: 11–16

    Article  PubMed  CAS  Google Scholar 

  38. Hatlebakk JG, Hyggen A, Madsen PH (1999) Heartburn treatment in primary care: randomised double-blind study for 8 weeks. BMJ 319: 550–554

    PubMed  CAS  Google Scholar 

  39. Malfertheiner P, Stolte M, Willich SN (submitted 2004) Prognostic influence of Barrett’s epithelium and of Helicobacter pylori infection on healing of erosive and non-erosive gastro-esophageal reflux disease — Report from the PROGORD Study

    Google Scholar 

  40. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC (1999) Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 94: 884–887

    Article  PubMed  CAS  Google Scholar 

  41. Carlsson R, Bate C, Dent J (1997) Does Helicobacter pylori infection influence the response to treatment with acid inhibition in patiens with GORD? Scand J Gastroenterol 32(Suppl 224): F70

    Google Scholar 

  42. Peter FTM, Kuipers EJ, Ganesh S (1999) The influence of Helicobacter pylori on oesophageal acid exposure in GORD during acid supressive therapy. Aliment Pharmacol Ther 13: 921–926

    Article  Google Scholar 

  43. Vakikl N, Kahrilas P, Magner D (2000) Does baseline Helicobacter pylori status impact erosive esophagitis healing rates? Am J Gastroenterol 95: 2438A

    Article  Google Scholar 

  44. Kuipers EJ, Lundell L, Klinkenberg-Knol EC (1996) Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334: 1018–1022

    Article  PubMed  CAS  Google Scholar 

  45. McColl (2004) Helicobacter pylori infection and long term proton pump inhibitor therapy, Gut 53: 5–7

    Article  PubMed  CAS  Google Scholar 

  46. Lundell L, Miettinen P, Myrvold HE (1999) Lack of effect of acid suppression therapy on gastric atrophy. Nodic GORD Study Group. Gastroenterology 117: 319–326

    Article  PubMed  CAS  Google Scholar 

  47. Uemura N, Okamoto S, Ymamoto S (2000) Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid — suppressive treatment in Japan. Aliment Pharmacol Ther 14: 1345–1352

    Article  PubMed  CAS  Google Scholar 

  48. Geboes K, Dekker W, Mulder Cjj (2001) Longterm lansoprazole treatment for gastroesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther 18: 1819–1826

    Article  Google Scholar 

  49. Stolte M, Meining A, Schmitz JM (1998) Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastroesophageal reflux disease. Aliment Pharmacol Ther 12: 247–253

    Article  PubMed  CAS  Google Scholar 

  50. Singh P, Indaram A, Greenberg R (2000) Long term omeprazole therapy for reflux esophagitis: follow-up in serum gastin levels, EC cell hyperplasia and neoplasia. World J Gastroenterol 6: 789–792

    PubMed  CAS  Google Scholar 

  51. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC (2001) Helicobacter eradication for the prevention of atrophic gastritis during omeprazole therapy; a prospective randomised trial. Gastroenterology 120(Suppl 1): A14

    Google Scholar 

  52. Uemura N, Okamoto S, Yamamoto S (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784–789

    Article  PubMed  CAS  Google Scholar 

  53. Malfertheiner P, Megraud F, O’Morain C (2002) Current concepts in the management of Helicobacter pylori infection — the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16: 167–180

    Article  PubMed  CAS  Google Scholar 

  54. Weston AP, Sharma P, Mathur S, Banerjee S, Jafri K, Cherian R, McGregor D, Hassanein RS, Hall M (2004) Risk stratification of Barrett’s esophagus: updated prospective multivariate analysis. Am J Gastroenterol 99: 1657

    Article  PubMed  Google Scholar 

  55. Abe Y, Ohara S, Koike T, Sekine H, Lijima K, Kawamura M, Imatani A, Kato K, Shimosegawa T (2004) The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with Barrett’s esophagus in Japan. Am J Gastroenterol 99: 1222–1225

    Article  Google Scholar 

  56. Clark GWB (2003) Effect of Helicobacter pylori infection in barrett’s esophagus and the genesis of esophageal adenocarcinoma. World J Surgery

    Google Scholar 

  57. Pearsonnet J, Friedman GD, Orentrich N, Vogelman H (1997) Risk for gastric cancer in people with cagApositive or cagA-negative Helicobacter pylori infection. Gut 40: 297–301

    Google Scholar 

  58. Chow WA, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, Risch HA (1998) An inverse relation between cagA+ strains of Helicobcter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 58: 588–590

    PubMed  CAS  Google Scholar 

  59. Ackermark P, Kuipers EJ, Wolf C, Breuemlhof R, Seldenrijk CA, Timmer R, Segeren KC, Kusters JG, Smout AJ (2003) Colonization with cagA-positive Helicobacter pylori strains in intestinal metaplasia of the esophagus and the esophagogastric junction. Am J Gastroenterol 98: 1719–1724

    Article  PubMed  Google Scholar 

  60. Forman D (2004) Review article: oesophago-gastric adenocarcinoma — an epidemiological perspective. Aliment Pharmacol Ther 20(Suppl 5): 55–60

    Article  PubMed  Google Scholar 

  61. Quddus MR, Henley JD, Sulaiman RA (1997) Helicobacter pylori infection and adenocarcinoma arising in Barrett’s esophagus. Hum Pathol 28: 1007–1009

    Article  PubMed  CAS  Google Scholar 

  62. Wright TA, Myskow M, Kingsnorth AN (1997) Helicobacter pylori colonization of Barrett’s esophagus and its progression to cancer. Dis Esophagus 10: 196–200

    PubMed  CAS  Google Scholar 

  63. Jones AD, Bacon KD, Jobe BA, Sheppard BC, Deveney CW, Rutten JM (2003) Helicobacter pylori induces apoptosis in Barrett’s derived esophageal adenocarcinoma cells. J Gastrointest Surg 7: 68–76

    Article  PubMed  Google Scholar 

  64. Deves SS, Blot WJ, Fraumeni JF Jr (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83(10): 2049–2053

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hepatology and Infectiology, Otto-von-Guericke-Universität Magdeburg, Magdeburg, Germany

    C. Knippig & P. Malfertheiner

Authors
  1. C. Knippig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Malfertheiner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Allgemein öffentliches Krankenhaus, Zell am See, Austria

    Frank A. Granderath , Thomas Kamolz  & Rudolph Pointner ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag/Wien

About this chapter

Cite this chapter

Knippig, C., Malfertheiner, P. (2006). The Intriguing Relationship of Helicobacter Pylori Infection and Gastro-Oesophageal Reflux Disease. In: Granderath, F.A., Kamolz, T., Pointner, R. (eds) Gastroesophageal Reflux Disease. Springer, Vienna. https://doi.org/10.1007/3-211-32317-1_6

Download citation

  • DOI: https://doi.org/10.1007/3-211-32317-1_6

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-23589-8

  • Online ISBN: 978-3-211-32317-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation